Today is shaping up negative for NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) shareholders, with the analysts delivering a substantial negative revision to next year's forecasts. There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that previous forecasts were much too optimistic.
Following the downgrade, the latest consensus from NewAmsterdam Pharma's 16 analysts is for revenues of US$46m in 2027, which would reflect a major 78% improvement in sales compared to the last 12 months. Losses are supposed to balloon 22% to US$2.09 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$52m and losses of US$2.06 per share in 2027. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also making no real change to the loss per share numbers.
Check out our latest analysis for NewAmsterdam Pharma
The consensus price target was broadly unchanged at €46.06, implying that the business is performing roughly in line with expectations, despite a downwards adjustment to forecast sales next year. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic NewAmsterdam Pharma analyst has a price target of €54.70 per share, while the most pessimistic values it at €34.08. This shows there is still some diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. One thing stands out from these estimates, which is that NewAmsterdam Pharma is forecast to grow faster in the future than it has in the past, with revenues expected to display 59% annualised growth until the end of 2027. If achieved, this would be a much better result than the 21% annual decline over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 21% annually. So it looks like NewAmsterdam Pharma is expected to grow faster than its competitors, at least for a while.
While analysts did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on NewAmsterdam Pharma after today.
Even so, the longer term trajectory of the business is much more important for the value creation of shareholders. At Simply Wall St, we have a full range of analyst estimates for NewAmsterdam Pharma going out to 2028, and you can see them free on our platform here.
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.